Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 114

PerkinElmer has moved to expand its life sciences portfolio with CRISPR and gene editing offerings by snapping up the cell engineering specialist Horizon Discovery.

The $383 million, all-cash deal will add gene modulation tools that—in combination with its own work in applied genomics solutions—aims to provide next-generation research tools and the customized cell lines necessary for developers of new targeted therapies, and broaden PerkinElmer’s partnership work with academic researchers and the biopharma industry.

The Cambridge, U.K.-based Horizon, with about 400 employees worldwide with offices in the U.S. and Japan, provides genetic base editing technologies for living cell models using CRISPR reagents, as well as gene modulation products using RNA interference methods.

Read more | >

Three actions policymakers and business leaders can take today.

New developments in AI could spur a massive democratization of access to services and work opportunities, improving the lives of millions of people around the world and creating new commercial opportunities for businesses. Yet they also raise the specter of potential new social divides and biases, sparking a public backlash and regulatory risk for businesses. For the U.S. and other advanced economies, which are increasingly fractured along income, racial, gender, and regional lines, these questions of equality are taking on a new urgency. Will advances in AI usher in an era of greater inclusiveness, increased fairness, and widening access to healthcare, education, and other public services? Or will they instead lead to new inequalities, new biases, and new exclusions?

Three frontier developments stand out in terms of both their promised rewards and their potential risks to equality. These are human augmentation, sensory AI, and geographic AI.

Human Augmentation

Variously described as biohacking or Human 2.0, human augmentation technologies have the potential to enhance human performance for good or ill.

Read more | >

Human body bio-factories of tommorow for organ and tissue replacement.

Ira Pastor, ideaXme life sciences ambassador interviews Dr Alexander Titus Chief Strategy Officer (CSO) at the Advanced Regenerative Manufacturing Institute (ARMI).

Ira Pastor comments:

The Advanced Regenerative Manufacturing Institute (ARMI) is one of 14 institutes of the Manufacturing USA network, and is a member-driven, non-profit organization, whose mission is to make practical the large-scale manufacturing of engineered tissues and tissue-related technologies.

BioFabUSA, created by ARMI, was established to lead the charge in large-scale manufacturing of engineered tissues and regenerative medicine research, turning foundational breakthroughs in the manufacture of engineered tissues and tissue-related technologies into life-changing possibilities for everyone.

Continue reading “Advanced Technology: Science Fiction to Science Fact and Encouraging a Culture of Responsibility” | >

One of the most important questions in science is how life began on Earth.

One theory is that wet-dry cycling on the early Earth—whether through rainy/dry periods, or through phenomena such as geysers—encouraged molecular complexity. The hydration/rehydration cycle is thought to have created conditions that allowed membraneless compartments called complex coacervates to act as homes for chemicals to combine to create life.

Using the Advanced Photon Source at Argonne National Laboratory, scientists in the Pritzker School of Molecular Engineering (PME) at the University of Chicago studied these compartments as they undergo phase changes to understand just what happens inside them during wet-dry cycle.

Read more | >

KENNEDY SPACE CENTER (FL), October 19, 2020 – The Center for the Advancement of Science in Space (CASIS) and the National Science Foundation (NSF) announced three flight projects that were selected as part of a joint solicitation focused on leveraging the International Space Station (ISS) U.S. National Laboratory to further knowledge in the fields of tissue engineering and mechanobiology. Through this collaboration, CASIS, manager of the ISS National Lab, will facilitate hardware implementation, in-orbit access, and astronaut crew time on the orbiting laboratory. NSF invested $1.2 million in the selected projects, which are seeking to advance fundamental science and engineering knowledge for the benefit of life on Earth.

This is the third collaborative research opportunity between CASIS and NSF focused on tissue engineering. Fundamental science is a major line of business for the ISS National Lab, and by conducting research in the persistent microgravity environment offered by the orbiting laboratory, NSF and the ISS National Lab will drive new advances that will bring value to our nation and spur future inquiries in low Earth orbit.

Microgravity affects organisms—from viruses and bacteria to humans, inducing changes such as altered gene expression and DNA regulation, changes in cellular function and physiology, and 3D aggregation of cells. Spaceflight is advancing research in the fields of pharmaceutical research, disease modeling, regenerative medicine, and many other areas within the life sciences. The selected projects will utilize the ISS National Lab and its unique environment to advance fundamental and transformative research that integrates engineering and life sciences.

Read more | >

“This is kind of a nice bookend to 16 years of research,” says Deisseroth, a neuroscientist and bioengineer at Stanford University. “It took years and years for us to sort out how to make it work.”

“The result is described this month in the journal Nature Biotechnology.”

“Optogenetics involves genetically engineering animal brains to express light-sensitive proteins—called opsins—in the membranes of neurons.”

Optogenetics can now control neural circuits at unprecedented depths within living brain tissue without surgery.

Read more | >

A team of researchers at Duke University have developed an imaging technology for tagging structures at a cellular level that overcomes the shortcomings of existing antibody-based techniques. Immunofluorescence imaging is a key part of the cell biologist’s toolbox, in which a fluorescent ‘flare’ attached to an antibody allows them to visualize the presence of specific target proteins in cell or tissue samples. The issue is that this specificity isn’t always 100 percent — sometimes the antibodies bind to other closely related proteins as well, making it difficult to interpret the results.

Duke’s cell biology chair Scott Soderling has led a team that developed Homology-independent Universal Genome Engineering (HiUGE), an innovation that uses gene-editing technology to rise above the shortcomings of traditional commercial antibodies for imaging.

“We had this idea that CRISPR could be a really amazing tool to address the pressing problem of trying to identify and label these hundreds of proteins,” said Soderling.

Read more | >

Dr. Adam Freund PhD., Calico Life Sciences, Discussing Google Quest to Solve Aging.

Ira Pastor, ideaXme life sciences ambassador interviews Dr Adam Freund, PhD, Principal Investigator at Calico Life Sciences (Calico). https://www.calicolabs.com

Ira Pastor comments:

Calico is a research and development focused biotechnology company founded and backed by Google / Alphabet with the goal of combating aging and associated age-related diseases.

Calico has a billion dollar partnership with the bio-pharma giant AbbVie, focused on aging and age-related diseases, such as neuro-degeneration and cancer. Calico also has partnerships with the University of Texas Southwestern Medical Center and 2M Companies (regarding drug development for neurodegenerative disorders), the Broad Institute of MIT and Harvard (to advance research on age-related diseases and therapeutics), and a partnership with the Buck Institute for Research on Aging.

Continue reading “Google / Alphabet’s Quest to Solve Aging” | >